​Our FLEX-NK™ cell engagers are trispecific, bifunctional antibodies designed to engage NK cells through NKp46 and CD16 and tumors through specific antigen targets such as GPC3 for HCC. Their ability to engage with multiple targets enhances the recruitment and killing ability of immune cells at tumor sites. By aiming for greater precision in targeting disease cells while sparing healthy tissues, these antibodies show potential to improve efficacy while reducing toxicity, even at higher doses. This multifaceted approach - capable of synergistically combining actions such as inhibiting tumor growth, promoting immune activation, and blocking angiogenesis – shows promise for improved therapeutic outcomes compared to monoclonal therapies, particularly with more complex and resistant cancers. 

​

​

​​

​

​​

​

​

​

​

​

​

​

​

​

NKp46 is an NK cell activator that significantly enhances the depth and durability of biological response beyond the antibody’s half-life. NKp46 drives increased trafficking of NK cells from the periphery to the tumor micro-environment (TME), reverses functional exhaustion of NK cells, and provides sustained cell engagement, maintaining conjugate time and serial killing. Dual trigger signaling of NKp46 and CD16 increases cytotoxicity even in suppressive environments.

​

​

​

​

​

​

​​​

​

​

​

​

​

​

 

NY-303, our lead FLEX-NK™ cell engager, is a GPC3/NKp46-targeting bifunctional antibody positioned as a potential best-in-class second-line therapy for the treatment of refractory hepatocellular carcinoma (HCC). It is differentiated by a unique mechanism of action designed to unlock the biology of non-responders to PD(L)1 Inhibitors (+/- VEGF Inhibitors) - 70-85% of HCC patients - and is cleared to enroll patients in a Phase I/IIa monotherapy trial in H2 2025.​​​​​​​​